Compare Bristol-Myers Squibb Co (BMY) vs McDonald's Corp (MCD) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

McDonald's (MCD) trades at $272.61, down 0.72% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $26.89 billion in 2025, with a net income margin of 31.62%, and recently unveiled its 'McDonald's NEXT' growth strategy focusing on automation and menu innovation. Analyst consensus is a Buy with a $325.50 price target, indicating significant upside potential.

The outlook for MCD is positive due to strong fundamentals, consistent profitability, and strategic initiatives to drive growth. Key risks include inflationary pressures on franchisee margins and competitive threats. The stock presents a long-term opportunity supported by analyst optimism and a resilient business model, though near-term volatility may persist.